Evidence map›Paper›PMID 17392473›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2007

Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.

Jim P Dompierre, Juliette D Godin, Bénédicte C Charrin, Fabrice P Cordelières, Stephen J King, Sandrine Humbert, Frédéric Saudou

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 396 papers.

0numbers the graph read from it
0cells of the map it votes in
396citing papers in PubMed
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

396 citing papers in PubMed, 771 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Tubulin Acetylation: A Critical Regulator of Microtubule Function.Results and problems in cell differentiation · 2025
    Review
  18. Article
  19. Review
  20. Article

336 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Jim P DompierreInstitut Curie and Centre National de la Recherche Scientifique Unité Mixte de Recherche 146, Orsay, France.
Juliette D Godin
Bénédicte C Charrin
Fabrice P Cordelières
Stephen J King
Sandrine Humbert
Frédéric Saudou
Centre National de la Recherche Scientifique · FRUniversity of Missouri–Kansas City · US

Funding

BRAIN TISSUE RESOURCE OFR NEUROPSYCHIATRIC RESEARCHR01MH031862 · NIMH · MC LEAN HOSPITAL (BELMONT, MA) · PI BENES, FRANCINE M. · 1985 to 2002
$3.6M
Dynactin/microtubule interactions in dynein motilityR01NS048501 · NINDS · UNIVERSITY OF MISSOURI KANSAS CITY · PI KING, STEPHEN J · 2004 to 2014
$2.9M
NIMH NIH HHS MH/NS 31862NINDS NIH HHS NS 48501NINDS NIH HHS R01 NS048501
6 · The paper itself

Abstract

A defect in microtubule (MT)-based transport contributes to the neuronal toxicity observed in Huntington's disease (HD). Histone deacetylase (HDAC) inhibitors show neuroprotective effects in this devastating neurodegenerative disorder. We report here that HDAC inhibitors, including trichostatin A (TSA), increase vesicular transport of brain-derived neurotrophic factor (BDNF) by inhibiting HDAC6, thereby increasing acetylation at lysine 40 of alpha-tubulin. MT acetylation in vitro and in cells causes the recruitment of the molecular motors dynein and kinesin-1 to MTs. In neurons, acetylation at lysine 40 of alpha-tubulin increases the flux of vesicles and the subsequent release of BDNF. We show that tubulin acetylation is reduced in HD brains and that TSA compensates for the transport- and release-defect phenotypes that are observed in disease. Our findings reveal that HDAC6 inhibition and acetylation at lysine 40 of alpha-tubulin may be therapeutic targets of interest in disorders such as HD in which intracellular transport is altered.

Indexed as

Histone Deacetylase InhibitorsAcetylationAnimalsBiological Transport, ActiveBrain-Derived Neurotrophic FactorCell LineCells, CulturedCerebral CortexHistone Deacetylase 6Histone DeacetylasesHuntington DiseaseHydroxamic AcidsMiceMicroscopy, VideoMicrotubulesMolecular Motor ProteinsBrain-Derived Neurotrophic FactorHDAC6 protein, humanHistone Deacetylase 6Histone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsMolecular Motor ProteinsNeuroprotective Agentstrichostatin ATubulinVorinostat

Identifiers

PMID17392473
PMCPMC6672116
OpenAlexW2012887006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.